MYCO-005

{{Short description|Psychedelic drug}}

{{Infobox drug

| drug_name =

| image =

| width =

| caption =

| pronounce =

| tradename =

| Drugs.com =

| MedlinePlus =

| licence_CA =

| licence_EU =

| DailyMedID =

| licence_US =

| pregnancy_AU =

| pregnancy_category =

| dependency_liability =

| addiction_liability =

| routes_of_administration =

| class = Serotonin 5-HT_2A receptor agonist; Serotonergic psychedelic; Hallucinogen

| ATC_prefix =

| ATC_suffix =

| legal_status =

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action =

| excretion =

| CAS_number =

| CAS_supplemental =

| PubChem =

| PubChemSubstance =

| IUPHAR_ligand =

| DrugBank =

| ChemSpiderID =

| UNII =

| KEGG =

| ChEBI =

| ChEMBL =

| NIAID_ChemDB =

| PDB_ligand =

| synonyms = MYCO005

| IUPAC_name =

| C= | H= | N= | O=

| SMILES =

| StdInChI =

| StdInChIKey =

}}

MYCO-005 is a serotonin 5-HT_2A receptor agonist and psychedelic hallucinogen which is under development for the treatment of depressive disorders and anxiety disorders.{{cite web | title=Research programme: second generation psilocin analogs | website=AdisInsight | date=13 February 2024 | url=https://adisinsight.springer.com/drugs/800068546 | access-date=1 November 2024 | quote=A family of psilocin analogs (MYCO 005) with heart-safe microdose enabling properties is being developed by Mydecine Innovations Group for the treatment of [...]}}{{cite web | title=Delving into the Latest Updates on MYCO-005 with Synapse | website=Synapse | date=1 November 2024 | url=https://synapse.patsnap.com/drug/0cc4971130bd4ef2bda37dfaa4e8a07d | access-date=1 November 2024}}{{cite web | title=MYCO-005 Drug Profile | website=Ozmosi | date=26 October 2023 | url=https://pryzm.ozmosi.com/product/myco-005 | access-date=1 November 2024}}{{cite web | title=Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules | website=BioSpace | date=16 February 2022 | url=https://www.biospace.com/mydecine-announces-myco-005-family-of-improved-safety-microdose-novel-molecules | access-date=1 November 2024}}{{cite web | author=Mydecine Innovations Group | title=Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound | website=Yahoo Finance | date=18 December 2023 | url=https://finance.yahoo.com/news/mydecine-innovations-group-receives-notice-070000982.html | access-date=1 November 2024}}

It is an aza-indole analogue of psilocin and hence a tryptamine relative.{{cite web | title=Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds | website=BioSpace | date=7 February 2024 | url=https://www.biospace.com/mydecine-innovations-group-receives-two-notice-of-allowances-from-uspto-for-its-myco-005-and-myco-006-family-of-compounds | access-date=27 March 2025}} However, whereas psilocin and other tryptamines show high affinity for and potent activation of not only the serotonin 5-HT_2A receptor but also the serotonin 5-HT_2B receptor, MYCO-005 does not bind to this receptor. Activation of the serotonin 5-HT_2B receptor is known to induce the development of cardiac valvulopathy and has been a concern with regard to chronic microdosing of psychedelics.{{cite journal | vauthors = Tagen M, Mantuani D, van Heerden L, Holstein A, Klumpers LE, Knowles R | title = The risk of chronic psychedelic and MDMA microdosing for valvular heart disease | journal = J Psychopharmacol | volume = 37 | issue = 9 | pages = 876–890 | date = September 2023 | pmid = 37572027 | doi = 10.1177/02698811231190865 | url = }}{{cite journal | vauthors = Rouaud A, Calder AE, Hasler G | title = Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins | journal = J Psychopharmacol | volume = 38 | issue = 3 | pages = 217–224 | date = March 2024 | pmid = 38214279 | pmc = 10944580 | doi = 10.1177/02698811231225609 | url = }} Since MYCO-005 does not activate the serotonin 5-HT_2B receptor, it is anticipated to be heart-safe and to be safer for use in the contexts of both macro- and microdosing than other psychedelics.

As of February 2024, MYCO-005 is in the research stage of development for depressive disorders and anxiety disorders. It is being developed by Mydecine. The exact chemical structure of MYCO-005 does not yet seem to have been disclosed. However, the compound was patented in 2023 and the specified patent specifically describes aza-substituted psilocin analogues.{{cite web | title=Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | website=Google Patents | date=1 May 2023 | url=https://patents.google.com/patent/US20230348380A1/en?oq=US20230348380A1 | access-date=1 November 2024}}